Common therapeutic targets in cardiometabolic disease

The interactions between cardiovascular disease (CVD) and insulin resistance syndromes suggest the possibility of joint targets for cardiometabolic research. The best drugs would go beyond minimizing adverse effects and have protective actions against both metabolic disease and CVD. In this perspect...

Full description

Saved in:
Bibliographic Details
Published inScience translational medicine Vol. 6; no. 239; p. 239ps5
Main Authors Fredman, Gabrielle, Ozcan, Lale, Tabas, Ira
Format Journal Article
LanguageEnglish
Published United States 04.06.2014
Subjects
Animals
Calcium Signaling
Cardiovascular Diseases - therapy
Diabetes Mellitus, Type 2 - therapy
Endoplasmic Reticulum Stress
Humans
Inflammation - pathology
Molecular Targeted Therapy
Online AccessGet more information

Cover

More Information
Summary:The interactions between cardiovascular disease (CVD) and insulin resistance syndromes suggest the possibility of joint targets for cardiometabolic research. The best drugs would go beyond minimizing adverse effects and have protective actions against both metabolic disease and CVD. In this perspective, we will outline a few examples in which a deep mechanistic understanding of the many cellular pathways that contribute to type 2 diabetes and CVD, regardless of cell type, have resulted in common upstream pathogenic pathways that can be therapeutically targeted.
ISSN:1946-6242
DOI:10.1126/scitranslmed.3008908